Pig vaccine Cysvax prevents a form of epilepsy in humans

The outcome

A pig vaccine stops the spread of a tapeworm and prevents a form of human epilepsy in the developing world. The vaccine, Cysvax®, was based on research from the University of Melbourne.

The World Health Organization (WHO) recommends a combination of the vaccine and anti-parasitic drugs to stop the spread of the pork tapeworm, Taenia solium. The tapeworm passes from pigs to humans, where it can lead to epilepsy and death.

Use of Cysvax also protects the income of farmers, as tapeworm-infected pig meat is less valuable.

Cysvax was first registered for sale in India in 2016.

The need

The WHO has identified the pig tapeworm T. solium as a leading cause of death from food-borne diseases. Around 50 million people are infected worldwide.

In humans, infection with the larval form causes cysts throughout the body. This is called cysticercosis. Cysts in the brain or spinal cord can lead to confusion, headaches, blindness, seizures and death. This form of the disease, called neurocysticercosis, causes around 30 per cent of cases of human epilepsy in areas where the tapeworm is found.

As many as 8.3 million people worldwide have neurocysticercosis.

When pigs and humans live in close quarters with poor hygiene, the tapeworm cycles between the two species. Pigs are infected when they eat human faeces containing tapeworm eggs. Humans become infected when they eat pork containing tapeworm eggs.

Cysticercosis is common in subsistence farming communities across Latin America, Southeast Asia and Africa. The tapeworm is rare in developed countries, although there are around 1000 cases of cysticercosis in the USA each year.

Developing the solution

The vaccine was developed by a research team led by Professor Marshall Lightowlers from the Faculty of Veterinary and Agricultural Sciences at the University of Melbourne. As animal vaccines are easier and cheaper to develop than human vaccines, the researchers targeted pigs infected with T. solium.

In 2006, they extracted a gene from the tapeworm that encodes a protein called TSOL18. They used the gene to develop a recombinant vaccine based on this protein. The vaccine triggers an immune response in pigs that attacks tapeworm embryos.

The vaccine was tested in trials in Mexico, Cameroon, Honduras and Peru. It protected 99–100 per cent of vaccinated pigs from tapeworm infection.

In a mass treatment trial in Northern Peru, the vaccine was administered in combination with antiparasitic drugs to more than 50 000 pigs. More than 80 000 people in the region were treated with antiparasitic drugs. The intervention eliminated transmission of the disease in the communities involved in the trial.

In 2011, the University of Melbourne collaborated with the Global Alliance for Livestock Veterinary Medicines (GALVmed), a UK-based charity, to develop the vaccine for commercialisation. The University of Melbourne chose not to patent the vaccine technology, to reduce the costs of vaccination and enable widespread use of the vaccine. GALVmed entered into a non-exclusive agreement with Indian Immunologicals Limited to produce and sell the vaccine.

In 2016, Cysvax became the first vaccine licensed for cysticercosis.

In field trials of Cysvax and antiparasitic medication for pigs in Nepal, Uganda, Tanzania and Zambia, the combined treatment has eliminated any potential for treated animals to transmit the disease to humans.

Re-use this text

Please use the text of this article for your own purposes. The text is licensed under the Creative Commons Attribution (CC BY) 4.0 International license. This lets you copy, transform and share the text without restriction. We appreciate appropriate credit and links back to this website. Other content on this page (such as images, videos and logos) is not covered by the CC BY license and may not be used without permission from the copyright holder. If you have any questions about using this text, please contact the research web team.